Year: 2025
Type: article
Abstract: Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease with a complex and multifactorial etiology. Topical treatment remains the mainstay of therapy in AD and research in the pathogenesis of the disease led to the identification of aryl hydrocarbon receptor (AhR) as a target of a new topical treatment. AhR is an environment sensor highly expressed in the skin and a transcription factor with a key role in inflammatory and immune signaling networks. Tapinarof, an AhR agonist, is a new nonsteroidal topical agent applied to treat AD and psoriasis. Clinical trials have demonstrated its rapid and durable efficacy, favorable safety, and long-term tolerability, with minimal-to-no systemic absorption in adults and children. To confirm its long-term safety and efficacy across patient populations, ongoing and future trials and real-life studies will be essential . Tapinarof, an AhR agonist, is a new nonsteroidal topical agent applied to treat AD and psoriasis. It Trials demonstrated its rapid and durable efficacy, favorable safety, and long-term tolerability, with minimal-to-no systemic absorption in adults and children. To confirm its long-term safety and efficacy across patient populations, ongoing and future trials and real-life studies will be essential.
Institutions: Fatebenefratelli Hospital, Ospedale San Pietro Fatebenefratelli, Azienda Ospedaliera Sant'Andrea, Sapienza University of Rome, University of Campania "Luigi Vanvitelli", University of Pisa, Azienda USL di Bologna, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Bologna
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7215445022
